← Eichor
Study identifier: NCT07641790 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effects of Wearable Vibratory Devices on Arm Function in Subacute Stroke Patients

Condition: Hemiplegia · Stroke  ·  Sponsor: University of Faisalabad

PhaseNA
Planned participants30
Who can joinAll sexes, 30 Years to 60 Years
Healthy volunteersNo

About this study

Hemiplegia, or paralysis of one side of the body, often results from stroke and severely limits arm function. Standard physiotherapy helps, but recovery is often slow. This study tests if adding a wearable vibratory device to standard therapy improves arm movement better than standard therapy alone. Thirty patients with subacute stroke (3-6 months) will be split into two groups. One group will receive usual physiotherapy, while the other will receive usual physiotherapy plus the vibratory device for 8 weeks. Doctors will measure changes in spasticity (muscle stiffness), motor function, and daily independence before and after treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Dr. Anbreena Rasool, Doctor of Physical Therapy  ·  +92 345 79368  ·  anbreenarasool.DPT@tuf.edu.pk

Dr Muhammad Ateeb, PhD Public Health  ·  +923357333383  ·  mateeb.oric@tuf.edu.pk

Always discuss trial participation with your own doctor first.

Locations (1)

The University of FaisalabadFaisalābad, Punjab Province, PakistanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07641790